Belzutifan improves progression-free survival in advanced renal cell cancer
Belzutifan, a hypoxia-inducible factor 2α (HIF-2α) inhibitor, improves progression-free survival and objective responses over everolimus among patients with advanced clear-cell renal cell carcinoma, according to a study ...
Aug 23, 2024
0
0